Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/18615
Título
Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.
Autor(es)
Fecha de publicación
2022-04-14
Idioma
Inglés
Tipo de documento
research article
Resumen
Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome.
Palabras clave
Type A insulin resistance syndrome | diabetes | glucagon-like peptide-1 receptor agonist | insulin resistance | sodium-glucose cotransporter 2 inhibitor
MESH
Benzhydryl Compounds | Diabetes Mellitus | Glucagon-Like Peptides | Glucosides | Humans | Insulin | Insulin Resistance
DOI
Aparece en las colecciones
Acceso a texto completo